Pages
- Home
- Company
- Theranostic
- Sitemap
- Legals
- Diagnostics
- Auto-Immunity
- Connectivitis – ANA
- Connectivitis – ENA
- Rheumatoid Arthritis
- Auto-Immune Liver Diseases
- Vasculitis
- Celiac disease
- Antiphospholipids syndrome
- Auto-Immune Thyroiditis
- Pernicious anemia
- Inflammatory Bowel Disease (IBD)
- Diabetes mellitus type 1
- Other organ-specific autoantibodies
- Cytokines
- Quality Control – Auto-Immunity
- Genetics
- Allergy
- Infectious diseases
- Mycoplasma Pneumoniae
- Borrelia (Lyme)
- Chlamydia pneumonia
- Chlamydia trachomatis
- CMV (Cytomegalovirus)
- Influenza A/B
- Mycobacteria
- EBV (Epstein Barr virus)
- HPV (Papillomavirus humain)
- HSV (Herpes Simplex virus)
- Parasitology
- Parvovirus B19
- Rotavirus/Adenovirus
- Streptococcus B
- Tetanus
- RSV (Respiratory Syncitial Virus)
- Drug of Abuse (DOA)
- Other diagnoses
- Instrumentation
- Auto-Immunity
- Services
- Contacts
- AmplideX™ FMR1 articles
- AmplideX™ FMR1 posters
- BCR/ABL1 Quant™ articles
- BCR/ABL1 Quant™ posters
- Signature® KRAS/BRAF articles
- Signature® KRAS/BRAF posters
Catégories
- News (14)
- Press release (9)
Articles par catégories
News
- Theradiag receives 3rd CE mark approval for new anti-CCP in-vitro diagnostic kit in rheumatoid arthritis
- Revenues and Financial results for 2012 in line with expectations
- ESHG 2013 – 8th to 11th June 2013 at the “Palais des congrès” of PARIS
- THERADIAG granted 1.2 million euros by OSEO as part of the collaborative project CaReNA
- Theradiag receives CE mark approval for two new Lisa Tracker monitoring kits in theranostics
- Arab Health 2013, 28th to 31st January 2013, Dubai International Convention & Exhibition Centre
- Success of the Theradiag IPO : €8.2 million raised, global demand of €15.1 million, price set at the upper end of the offering range at €5.80.
- Theradiag announces the signature of a partnership agreement with Sebia for the development of a new diagnostic kit
- JIB 2012 – CNIT Paris la Défense
- Planet xMAP 2012 – 10 & 11 October Grimaldi Forum, Monaco
- New members appointed to Theradiag’s Board of Directors
- Theradiag acquires Prestizia and its highly innovative microRNA technology platform
- Congresses and Events 2012
- Biomedical Diagnostics (BMD) becomes Theradiag and moves into theranostics
Press release
- Theradiag receives 3rd CE mark approval for new anti-CCP in-vitro diagnostic kit in rheumatoid arthritis
- Revenues and Financial results for 2012 in line with expectations
- THERADIAG granted 1.2 million euros by OSEO as part of the collaborative project CaReNA
- Theradiag receives CE mark approval for two new Lisa Tracker monitoring kits in theranostics
- Success of the Theradiag IPO : €8.2 million raised, global demand of €15.1 million, price set at the upper end of the offering range at €5.80.
- Theradiag announces the signature of a partnership agreement with Sebia for the development of a new diagnostic kit
- New members appointed to Theradiag’s Board of Directors
- Theradiag acquires Prestizia and its highly innovative microRNA technology platform
- Biomedical Diagnostics (BMD) becomes Theradiag and moves into theranostics